WuXi Biologics Receives 2016 Asia Pacific Biologics CMO Growth Excellence Leadership Award from Frost & Sullivan
Dec 29, 2016
SHANGHAI, Dec. 29, 2016 -- WuXi Biologics, a leading open-access R&D capability and technology platform company dedicated to biologics and a WuXi AppTec Group company, today announced that it had received the 2016 Asia Pacific Biologics CMO Growth Excellence Leadership Award from Frost & Sullivan, a leading business research and consulting firm.
Growth Excellence Leadership Award is part of the Frost & Sullivan Asia Pacific Best Practices Awards series, which identify and honor best-in-class companies in Asia Pacific that demonstrate excellence. WuXi Biologics has been recognized for its strong growth performance and customer impact in the region. Frost & Sullivan cited WuXi Biologics’ above market, sustainable company growth, its strong ownership and superb service experience for customers.
"WuXi Biologics is one of the most research-driven, experienced, and technologically advanced participants in the APAC region." said Sanjeev Kumar, consultant at Frost & Sullivan’s Asia Pacific Transformational Health Practice. "The company has emerged as a preferred partner for customers with its broad therapeutic expertise, experience in navigating global regulations, and state-of-the-art systems scaled to client needs. The company has transformed itself into a fully Integrated Biologics Discovery, Development and Manufacturing Service Provider. For sustained growth, the company is investing wisely, broadly, and aggressively into building new capabilities and increasing capacity."
“WuXi Biologics is honored to be recognized by Frost & Sullivan,” said Dr. Chris Chen, CEO of WuXi Biologics, “The award truly reflects all of the efforts we have put forth to provide our customers with high-quality and best-in-class service to help accelerate biologics development from concept to commercialization.”
“We thank Frost & Sullivan for recognizing WuXi again,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec, “We also thank our customers and partners for their continued trust and support. WuXi is honored to play an important role in helping to bring better medicines faster to patients.”
About WuXi AppTec
WuXi AppTec is a leading global pharmaceutical, biopharmaceutical, and medical device open-access capability and technology platform company with global operations. As an innovation-driven and customer-focused company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions. With its industry-leading capabilities in small molecule R&D and manufacturing, biologics R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, medical device testing, and molecular testing and genomics, WuXi platform is enabling more than 2,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi's dream that "every drug can be made and every disease can be treated." Please visit http://www.wuxiapptec.com
About WuXi Biologics
WuXi Biologics, a WuXi AppTec Group company, is a leading open-access technology capability and technology platform to enable anyone and any company to develop biologics. As a premier Contract Discovery, Development and Manufacturing Organization (CDMO), WuXi Biologics provides our worldwide clients with the necessary expertise, quality and capacities to develop biologic drugs from concept to commercialization. Along with our WuXi AppTec affiliates, we provide the world with the ONE true single-source approach that saves our clients critical time and money. Our company history and achievements demonstrate our commitment to providing a truly ONE-stop service offering and value proposition to our global clients. For more information on WuXi's Biologics services, please visit:http://www.wuxibiologics.com.